{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:24:37Z","timestamp":1788452677136,"version":"build-2803163510"},"reference-count":82,"publisher":"Bentham Science Publishers Ltd.","issue":"6","funder":[{"DOI":"10.13039\/501100003196","name":"Rete Cardiologica of the Italian Ministry of Health","doi-asserted-by":"publisher","award":["2754291"],"award-info":[{"award-number":["2754291"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Despite a clear epidemiological link between autoimmune disease and cardiovascular\n(CV) risk exists, pathophysiological explanations are extremely complex and far\nfrom being elucidated. Dysregulation of metabolic pathways and chronic low-grade inflammation\nrepresent common pathways, but CV risk still remains underestimated in patients\nwith autoimmune diseases. Among different candidate mediators, pro-protein convertase\nsubtilisin\/kexin type 9 (PCSK9) is attracting growing attention, due to a combined\neffect on lipid metabolism and inflammatory response. Studies on PCSK9 inhibitors have\nestablished a clear benefit on CV outcome without an established effect on inflammation.\nConversely, evidence from sepsis and HIV infection strongly supports a pro-inflammatory\nrole of PCSK9. Still, the role of PCSK9 in autoimmune diseases is uncertain. So far, reported\nclinical findings are controversial and likely reflect the poor knowledge of PCSK9\nactivity on monocyte\/macrophage migration and activation. The complex signaling network\naround PCSK9 synthesis and metabolism may also have a role, especially concerning\nthe involvement of scavenger receptors, such as CD36. Such complexity in PCSK9\nsignaling seems particularly evident in autoimmune disease model. This would also potentially\nexplain the observed independency between lipid profile and PCSK9 levels, the\nso-called \u201clipid paradox\u201d. In this narrative review, we will summarize the current\nknowledge about the complex network of PCSK9 signaling. We will focus on upstream\nand downstream pathways with potential implication in autoimmune disease and potential\neffects of PCSK9 inhibiting strategies.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867328666210810150940","type":"journal-article","created":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T19:02:17Z","timestamp":1628622137000},"page":"970-979","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["PCSK9 and Inflammation: Their Role in Autoimmune Diseases, with\na Focus on Rheumatoid Arthritis and Systemic Lupus Erythematosus"],"prefix":"10.2174","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4358-6411","authenticated-orcid":true,"given":"Stefano","family":"Ministrini","sequence":"first","affiliation":[{"name":"Internal Medicine, Angiology and Atherosclerosis, Department of Medicine and Surgery, University of Perugia,\np.le Gambuli 1, 06132 Perugia, Italy | Center for Molecular Cardiology, University of Z\u00fcrich, Wagistrasse\n12, 8952 Schlieren, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2957-4078","authenticated-orcid":true,"given":"Federico","family":"Carbone","sequence":"additional","affiliation":[{"name":"First Clinic of internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, Italy | IRCCS Ospedale Policlinico San Martino,\nGenoa \u2013 Italian Cardiovascular Network, 10 Largo Benzi, 16132 Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1002\/art.41291","volume":"72","author":"Kawai V.K.","year":"2020","unstructured":"Kawai V.K.; Shi M.; Feng Q.; Chung C.P.; Liu G.; Cox N.J.; Jarvik G.P.; Lee M.T.M.; Hebbring S.J.; Harley J.B.; Kaufman K.M.; Namjou B.; Larson E.; Gordon A.S.; Roden D.M.; Stein C.M.; Mosley J.D.; Pleiotropy in the genetic predisposition to rheumatoid arthritis: a phenome-wide association study and inverse variance-weighted meta-analysis. Arthritis Rheumatol 2020,72(9),1483-1492","journal-title":"Arthritis Rheumatol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1160\/TH12-10-0768","volume":"109","author":"Carbone F.","year":"2013","unstructured":"Carbone F.; Nencioni A.; Mach F.; Vuilleumier N.; Montecucco F.; Evidence on the pathogenic role of auto-antibodies in acute cardiovascular diseases. Thromb Haemost 2013,109(5),854-868","journal-title":"Thromb Haemost"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/annrheumdis-2017-211735","volume":"77","author":"Crowson C.S.","year":"2018","unstructured":"Crowson C.S.; Rollefstad S.; Ikdahl E.; Kitas G.D.; van Riel P.L.C.M.; Gabriel S.E.; Matteson E.L.; Kvien T.K.; Douglas K.; Sandoo A.; Arts E.; W\u00e5llberg-Jonsson S.; Innala L.; Karpouzas G.; Dessein P.H.; Tsang L.; El-Gabalawy H.; Hitchon C.; Ramos V.P.; Y\u00e1\u00f1ez I.C.; Sfikakis P.P.; Zampeli E.; Gonzalez-Gay M.A.; Corrales A.; Laar M.V.; Vonkeman H.E.; Meek I.; Semb A.G.; Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Ann Rheum Dis 2018,77(1),48-54","journal-title":"Ann Rheum Dis"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1136\/annrheumdis-2017-212614","volume":"77","author":"Leonard D.","year":"2018","unstructured":"Leonard D.; Svenungsson E.; Dahlqvist J.; Alexsson A.; \u00c4rlestig L.; Taylor K.E.; Sandling J.K.; Bengtsson C.; Frodlund M.; J\u00f6nsen A.; Eketj\u00e4ll S.; Jensen-Urstad K.; Gunnarsson I.; Sj\u00f6wall C.; Bengtsson A.A.; Eloranta M.L.; Syv\u00e4nen A.C.; Rantap\u00e4\u00e4-Dahlqvist S.; Criswell L.A.; R\u00f6nnblom L.; Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 2018,77(7),1063-1069","journal-title":"Ann Rheum Dis"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12016-018-8714-z","volume":"58","author":"Carbone F.","year":"2020","unstructured":"Carbone F.; Bonaventura A.; Liberale L.; Paolino S.; Torre F.; Dallegri F.; Montecucco F.; Cutolo M.; Atherosclerosis in rheumatoid arthritis: promoters and opponents. Clin Rev Allergy Immunol 2020,58(1),1-14","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1136\/ard.2009.113696","volume":"69","author":"Peters M.J.","year":"2010","unstructured":"Peters M.J.; Symmons D.P.; McCarey D.; Dijkmans B.A.; Nicola P.; Kvien T.K.; McInnes I.B.; Haentzschel H.; Gonzalez-Gay M.A.; Provan S.; Semb A.; Sidiropoulos P.; Kitas G.; Smulders Y.M.; Soubrier M.; Szekanecz Z.; Sattar N.; Nurmohamed M.T.; EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010,69(2),325-331","journal-title":"Ann Rheum Dis"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1002\/acr.23018","volume":"69","author":"Avi\u00f1a-Zubieta J.A.","year":"2017","unstructured":"Avi\u00f1a-Zubieta J.A.; To F.; Vostretsova K.; De Vera M.; Sayre E.C.; Esdaile J.M.; Risk of myocardial infarction and stroke in newly diagnosed systemic lupus erythematosus: a general population-based study. Arthritis Care Res (Hoboken) 2017,69(6),849-856","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1136\/annrheumdis-2016-210973","volume":"76","author":"Arkema E.V.","year":"2017","unstructured":"Arkema E.V.; Svenungsson E.; Von Euler M.; Sj\u00f6wall C.; Simard J.F.; Stroke in systemic lupus erythematosus: a Swedish population-based cohort study. Ann Rheum Dis 2017,76(9),1544-1549","journal-title":"Ann Rheum Dis"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1007\/s12026-016-8808-8","volume":"64","author":"Li H.M.","year":"2016","unstructured":"Li H.M.; Zhang T.P.; Leng R.X.; Li X.P.; Li X.M.; Liu H.R.; Ye D.Q.; Pan H.F.; Emerging role of adipokines in systemic lupus erythematosus. Immunol Res 2016,64(4),820-830","journal-title":"Immunol Res"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/cells10020216","volume":"10","author":"Neumann E.","year":"2021","unstructured":"Neumann E.; Hasseli R.; Ohl S.; Lange U.; Frommer K.W.; M\u00fcller-Ladner U.; Adipokines and Autoimmunity in Inflammatory Arthritis. Cells 2021,10(2),10","journal-title":"Cells"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.imlet.2018.09.002","volume":"203","author":"D\u00edaz B.B.","year":"2018","unstructured":"D\u00edaz B.B.; Gonz\u00e1lez D.A.; Gannar F.; P\u00e9rez M.C.R.; de Le\u00f3n A.C.; Myokines, physical activity, insulin resistance and autoimmune diseases. Immunol Lett 2018,203,1-5","journal-title":"Immunol Lett"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/ijms21165678","volume":"21","author":"An H.J.","year":"2020","unstructured":"An H.J.; Tizaoui K.; Terrazzino S.; Cargnin S.; Lee K.H.; Nam S.W.; Kim J.S.; Yang J.W.; Lee J.Y.; Smith L.; Koyanagi A.; Jacob L.; Li H.; Shin J.I.; Kronbichler A.; Sarcopenia in autoimmune and rheumatic diseases: a comprehensive review. Int J Mol Sci 2020,21(16),21","journal-title":"Int J Mol Sci"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/ijms21249505","volume":"21","author":"Behl T.","year":"2020","unstructured":"Behl T.; Kaur I.; Sehgal A.; Zengin G.; Brisc C.; Brisc M.C.; Munteanu M.A.; Nistor-Cseppento D.C.; Bungau S.; The lipid paradox as a metabolic checkpoint and its therapeutic significance in ameliorating the associated cardiovascular risks in rheumatoid arthritis patients. Int J Mol Sci 2020,21(24),21","journal-title":"Int J Mol Sci"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s00393-016-0239-3","volume":"77","author":"Bes C.","year":"2018","unstructured":"Bes C.; G\u00fcrel S.; Bu\u011fdayc\u0131 G.; Dikba\u015f O.; Soy M.; Atherosclerosis assessment and rheumatoid arthritis. Z Rheumatol 2018,77(4),330-334","journal-title":"Z Rheumatol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/ehjcvp\/pvz022","volume":"5","author":"Momtazi-Borojeni A.A.","year":"2019","unstructured":"Momtazi-Borojeni A.A.; Sabouri-Rad S.; Gotto A.M.; Pirro M.; Banach M.; Awan Z.; Barreto G.E.; Sahebkar A.; PCSK9 and inflammation: a review of experimental and clinical evidence. Eur Heart J Cardiovasc Pharmacother 2019,5(4),237-245","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.atherosclerosis.2017.04.023","volume":"262","author":"Tang Z.H.","year":"2017","unstructured":"Tang Z.H.; Peng J.; Ren Z.; Yang J.; Li T.T.; Li T.H.; Wang Z.; Wei D.H.; Liu L.S.; Zheng X.L.; Jiang Z.S.; New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4\/NF-\u03baB pathway. Atherosclerosis 2017,262,113-122","journal-title":"Atherosclerosis"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1093\/cvr\/cvz313","volume":"116","author":"Ding Z.","year":"2020","unstructured":"Ding Z.; Pothineni N.V.K.; Goel A.; L\u00fcscher T.F.; Mehta J.L.; PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1. Cardiovasc Res 2020,116(5),908-915","journal-title":"Cardiovasc Res"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1093\/cvr\/cvv178","volume":"107","author":"Ding Z.","year":"2015","unstructured":"Ding Z.; Liu S.; Wang X.; Deng X.; Fan Y.; Shahanawaz J.; Shmookler Reis R.J.; Varughese K.I.; Sawamura T.; Mehta J.L.; Cross-talk between LOX-1 and PCSK9 in vascular tissues. Cardiovasc Res 2015,107(4),556-567","journal-title":"Cardiovasc Res"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1089\/ars.2016.6631","volume":"25","author":"Ding Z.","year":"2016","unstructured":"Ding Z.; Liu S.; Wang X.; Mathur P.; Dai Y.; Theus S.; Deng X.; Fan Y.; Mehta J.L.; Cross-talk between PCSK9 and damaged mtDNA in vascular smooth muscle cells: role in apoptosis. Antioxid Redox Signal 2016,25(18),997-1008","journal-title":"Antioxid Redox Signal"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jacl.2014.07.001","volume":"8","author":"Zhang Y.","year":"2014","unstructured":"Zhang Y.; Zhu C.G.; Xu R.X.; Li S.; Guo Y.L.; Sun J.; Li J.J.; Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease. J Clin Lipidol 2014,8(5),494-500","journal-title":"J Clin Lipidol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3109\/07853890.2015.1042908","volume":"47","author":"Li S.","year":"2015","unstructured":"Li S.; Zhang Y.; Xu R.X.; Guo Y.L.; Zhu C.G.; Wu N.Q.; Qing P.; Liu G.; Dong Q.; Li J.J.; Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease. Ann Med 2015,47(5),386-393","journal-title":"Ann Med"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1093\/eurheartj\/ehv637","volume":"37","author":"Gencer B.","year":"2016","unstructured":"Gencer B.; Montecucco F.; Nanchen D.; Carbone F.; Klingenberg R.; Vuilleumier N.; Aghlmandi S.; Heg D.; R\u00e4ber L.; Auer R.; J\u00fcni P.; Windecker S.; L\u00fcscher T.F.; Matter C.M.; Rodondi N.; Mach F.; Prognostic value of PCSK9 levels in patients with acute coronary syndromes. Eur Heart J 2016,37(6),546-553","journal-title":"Eur Heart J"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.abb.2017.06.001","volume":"625-626","author":"Melendez Q.M.","year":"2017","unstructured":"Melendez Q.M.; Krishnaji S.T.; Wooten C.J.; Lopez D.; Hypercholesterolemia: The role of PCSK9. Arch Biochem Biophys 2017,625-626,39-53","journal-title":"Arch Biochem Biophys"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/hep.22354","volume":"48","author":"Zaid A.","year":"2008","unstructured":"Zaid A.; Roubtsova A.; Essalmani R.; Marcinkiewicz J.; Chamberland A.; Hamelin J.; Tremblay M.; Jacques H.; Jin W.; Davignon J.; Seidah N.G.; Prat A.; Proprotein convertase subtilisin\/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology 2008,48(2),646-654","journal-title":"Hepatology"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"462","DOI":"10.5551\/jat.RV17003","volume":"24","author":"Shapiro M.D.","year":"2017","unstructured":"Shapiro M.D.; Fazio S.; PCSK9 and Atherosclerosis - Lipids and Beyond. J Atheroscler Thromb 2017,24(5),462-472","journal-title":"J Atheroscler Thromb"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.atherosclerosis.2011.11.026","volume":"220","author":"Ferri N.","year":"2012","unstructured":"Ferri N.; Tibolla G.; Pirillo A.; Cipollone F.; Mezzetti A.; Pacia S.; Corsini A.; Catapano A.L.; Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis 2012,220(2),381-386","journal-title":"Atherosclerosis"},{"key":"ref=27","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002426","volume":"94","author":"Li J.J.","year":"2015","unstructured":"Li J.J.; Li S.; Zhang Y.; Xu R.X.; Guo Y.L.; Zhu C.G.; Wu N.Q.; Qing P.; Gao Y.; Sun J.; Liu G.; Dong Q.; Proprotein convertase subtilisin\/kexin type 9, c-reactive protein, coronary severity, and outcomes in patients with stable coronary artery disease: a prospective observational cohort study. Medicine (Baltimore) 2015,94(52)","journal-title":"Medicine (Baltimore)"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s12265-020-10050-3","volume":"14","author":"Acena A.","year":"2021","unstructured":"Acena A.; Franco Pelaez J.A.; Pello Lazaro A.M.; Gonzalez Parra E.; Gonzalez Lorenzo O.; Martinez-Milla J.; Hernandez I.; Martin-Mariscal M.L.; Lopez Castillo M.; Kallmeyer A.; Lorenzo O.; Gonzalez-Casaus M.L.; Egido J.; Tunon J.; PCSK9 and HS-CRP Predict Progression of Aortic Stenosis in Patients with Stable Coronary Artery Disease. J Cardiovasc Transl Res 2021,14(2),238-245","journal-title":"J Cardiovasc Transl Res"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.atherosclerosis.2020.11.025","volume":"316","author":"Kheirkhah A.","year":"2021","unstructured":"Kheirkhah A.; Lamina C.; Rantner B.; Kollerits B.; Stadler M.; Pohlhammer J.; Klein-Weigel P.; Fraedrich G.; Kronenberg F.; Elevated levels of serum PCSK9 in male patients with symptomatic peripheral artery disease: The CAVASIC study. Atherosclerosis 2021,316,41-47","journal-title":"Atherosclerosis"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"Sabatine M.S.","year":"2017","unstructured":"Sabatine M.S.; Giugliano R.P.; Keech A.C.; Honarpour N.; Wiviott S.D.; Murphy S.A.; Kuder J.F.; Wang H.; Liu T.; Wasserman S.M.; Sever P.S.; Pedersen T.R.; Committee F.S.; Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017,376,1713-1722","journal-title":"N Engl J Med"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.jacc.2018.10.039","volume":"73","author":"Szarek M.","year":"2019","unstructured":"Szarek M.; White H.D.; Schwartz G.G.; Alings M.; Bhatt D.L.; Bittner V.A.; Chiang C.E.; Diaz R.; Edelberg J.M.; Goodman S.G.; Hanotin C.; Harrington R.A.; Jukema J.W.; Kimura T.; Kiss R.G.; Lecorps G.; Mahaffey K.W.; Moryusef A.; Pordy R.; Roe M.T.; Tricoci P.; Xavier D.; Zeiher A.M.; Steg P.G.; Committees O.O.; Alirocumab reduces total nonfatal cardiovascular and fatal events: the odyssey outcomes trial. J Am Coll Cardiol 2019,73(4),387-396","journal-title":"J Am Coll Cardiol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.atherosclerosis.2019.07.015","volume":"288","author":"Ruscica M.","year":"2019","unstructured":"Ruscica M.; Tokg\u00f6zo\u011flu L.; Corsini A.; Sirtori C.R.; PCSK9 inhibition and inflammation: A narrative review. Atherosclerosis 2019,288,146-155","journal-title":"Atherosclerosis"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","volume":"376","author":"Ray K.K.","year":"2017","unstructured":"Ray K.K.; Landmesser U.; Leiter L.A.; Kallend D.; Dufour R.; Karakas M.; Hall T.; Troquay R.P.; Turner T.; Visseren F.L.; Wijngaard P.; Wright R.S.; Kastelein J.J.; Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med 2017,376(15),1430-1440","journal-title":"N Engl J Med"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jacc.2018.04.054","volume":"72","author":"Rosenson R.S.","year":"2018","unstructured":"Rosenson R.S.; Hegele R.A.; Fazio S.; Cannon C.P.; The evolving future of PCSK9 inhibitors. J Am Coll Cardiol 2018,72(3),314-329","journal-title":"J Am Coll Cardiol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1097\/SHK.0000000000000682","volume":"46","author":"Dwivedi D.J.","year":"2016","unstructured":"Dwivedi D.J.; Grin P.M.; Khan M.; Prat A.; Zhou J.; Fox-Robichaud A.E.; Seidah N.G.; Liaw P.C.; Differential expression of PCSK9 modulates infection, inflammation, and coagulation in a murine model of sepsis. Shock 2016,46(6),672-680","journal-title":"Shock"},{"key":"ref=36","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008782","volume":"6","author":"Walley K.R.","year":"2014","unstructured":"Walley K.R.; Thain K.R.; Russell J.A.; Reilly M.P.; Meyer N.J.; Ferguson J.F.; Christie J.D.; Nakada T.A.; Fjell C.D.; Thair S.A.; Cirstea M.S.; Boyd J.H.; PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Sci Transl Med 2014,6(258)","journal-title":"Sci Transl Med"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000442976","volume":"8","author":"Boyd J.H.","year":"2016","unstructured":"Boyd J.H.; Fjell C.D.; Russell J.A.; Sirounis D.; Cirstea M.S.; Walley K.R.; Increased plasma PCSK9 levels are associated with reduced endotoxin clearance and the development of acute organ failures during sepsis. J Innate Immun 2016,8(2),211-220","journal-title":"J Innate Immun"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"10496","DOI":"10.1038\/s41598-018-28777-0","volume":"8","author":"Grin P.M.","year":"2018","unstructured":"Grin P.M.; Dwivedi D.J.; Chathely K.M.; Trigatti B.L.; Prat A.; Seidah N.G.; Liaw P.C.; Fox-Robichaud A.E.; Low-density lipoprotein (LDL)-dependent uptake of Gram-positive lipoteichoic acid and Gram-negative lipopolysaccharide occurs through LDL receptor. Sci Rep 2018,8(1),10496","journal-title":"Sci Rep"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"10588","DOI":"10.1038\/s41598-019-46745-0","volume":"9","author":"Leung A.K.K.","year":"2019","unstructured":"Leung A.K.K.; Genga K.R.; Topchiy E.; Cirstea M.; Shimada T.; Fjell C.; Russell J.A.; Boyd J.H.; Walley K.R.; Reduced Proprotein convertase subtilisin\/kexin 9 (PCSK9) function increases lipoteichoic acid clearance and improves outcomes in Gram positive septic shock patients. Sci Rep 2019,9(1),10588","journal-title":"Sci Rep"},{"key":"ref=40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0155030","volume":"11","author":"Topchiy E.","year":"2016","unstructured":"Topchiy E.; Cirstea M.; Kong H.J.; Boyd J.H.; Wang Y.; Russell J.A.; Walley K.R.; Lipopolysaccharide is cleared from the circulation by hepatocytes via the low density lipoprotein receptor. PLoS One 2016,11(5)","journal-title":"PLoS One"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/joim.12946","volume":"286","author":"Rannikko J.","year":"2019","unstructured":"Rannikko J.; Jacome Sanz D.; Ortutay Z.; Seiskari T.; Aittoniemi J.; Huttunen R.; Syrj\u00e4nen J.; Pesu M.; Reduced plasma PCSK9 response in patients with bacteraemia is associated with mortality. J Intern Med 2019,286(5),553-561","journal-title":"J Intern Med"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/joim.13150","volume":"289","author":"Vecchi\u00e9 A.","year":"2021","unstructured":"Vecchi\u00e9 A.; Bonaventura A.; Meessen J.; Novelli D.; Minetti S.; Elia E.; Ferrara D.; Ansaldo A.M.; Scaravilli V.; Villa S.; Ferla L.; Caironi P.; Latini R.; Carbone F.; Montecucco F.; Investigators A.B.S.; PCSK9 is associated with mortality in patients with septic shock: data from the ALBIOS study. J Intern Med 2021,289(2),179-192","journal-title":"J Intern Med"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10238-020-00658-9","volume":"21","author":"Innocenti F.","year":"2021","unstructured":"Innocenti F.; Gori A.M.; Giusti B.; Tozzi C.; Donnini C.; Meo F.; Giacomelli I.; Ralli M.L.; Sereni A.; Sticchi E.; Tassinari I.; Marcucci R.; Pini R.; Plasma PCSK9 levels and sepsis severity: an early assessment in the emergency department. Clin Exp Med 2021,21(1),101-107","journal-title":"Clin Exp Med"},{"key":"ref=44","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.11130","volume":"2","author":"Feng Q.","year":"2019","unstructured":"Feng Q.; Wei W.Q.; Chaugai S.; Carranza Leon B.G.; Kawai V.; Carranza Leon D.A.; Jiang L.; Zhong X.; Liu G.; Ihegword A.; Shaffer C.M.; Linton M.F.; Chung C.P.; Stein C.M.; A genetic approach to the association between PCSK9 and sepsis. JAMA Netw Open 2019,2(9)","journal-title":"JAMA Netw Open"},{"key":"ref=45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210808","volume":"14","author":"Mitchell K.A.","year":"2019","unstructured":"Mitchell K.A.; Moore J.X.; Rosenson R.S.; Irvin R.; Guirgis F.W.; Shapiro N.; Safford M.; Wang H.E.; PCSK9 loss-of-function variants and risk of infection and sepsis in the reasons for geographic and racial differences in stroke (REGARDS) cohort. PLoS One 2019,14(2)","journal-title":"PLoS One"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1097\/QAD.0000000000001633","volume":"31","author":"Boccara F.","year":"2017","unstructured":"Boccara F.; Ghislain M.; Meyer L.; Goujard C.; Le May C.; Vigouroux C.; Bastard J.P.; Fellahi S.; Capeau J.; Cohen A.; Cariou B.; Impact of protease inhibitors on circulating PCSK9 levels in HIV-infected antiretroviral-naive patients from an ongoing prospective cohort. AIDS 2017,31(17),2367-2376","journal-title":"AIDS"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/hiv.12884","volume":"21","author":"Bianconi V.","year":"2020","unstructured":"Bianconi V.; Schiaroli E.; Pirro M.; Cardaci S.; Busti C.; Mannarino M.R.; Baldelli F.; Francisci D.; Effects of antiretroviral therapy on proprotein convertase subtilisin\/kexin 9: focus on lipids, inflammation and immunovirological parameters. HIV Med 2020,21(8),512-522","journal-title":"HIV Med"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.atherosclerosis.2019.02.015","volume":"284","author":"Gencer B.","year":"2019","unstructured":"Gencer B.; Pagano S.; Vuilleumier N.; Satta N.; Delhumeau-Cartier C.; Meier C.; Bavamian S.; Montecucco F.; Mach F.; Calmy A.; Clinical, behavioral and biomarker predictors of PCSK9 levels in HIV-infected patients na\u00efve of statin therapy: A cross-sectional analysis from the Swiss HIV cohort. Atherosclerosis 2019,284,253-259","journal-title":"Atherosclerosis"},{"key":"ref=49","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx227","volume":"4","author":"Zanni M.V.","year":"2017","unstructured":"Zanni M.V.; Stone L.A.; Toribio M.; Rimmelin D.E.; Robinson J.; Burdo T.H.; Williams K.; Fitch K.V.; Lo J.; Grinspoon S.K.; Proprotein convertase subtilisin\/kexin 9 levels in relation to systemic immune activation and subclinical coronary plaque in HIV. Open Forum Infect Dis 2017,4(4)","journal-title":"Open Forum Infect Dis"},{"key":"ref=50","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009996","volume":"7","author":"Leucker T.M.","year":"2018","unstructured":"Leucker T.M.; Weiss R.G.; Sch\u00e4r M.; Bonanno G.; Mathews L.; Jones S.R.; Brown T.T.; Moore R.; Afework Y.; Gerstenblith G.; Hays A.G.; Coronary endothelial dysfunction is associated with elevated serum PCSK9 levels in people with HIV independent of low-density lipoprotein cholesterol. J Am Heart Assoc 2018,7(19)","journal-title":"J Am Heart Assoc"},{"key":"ref=51","first-page":"1013","volume":"34","author":"Ferraz-Amaro I.","year":"2016","unstructured":"Ferraz-Amaro I.; L\u00f3pez-Mej\u00edas R.; Ubilla B.; Genre F.; Tejera-Segura B.; de Vera-Gonz\u00e1lez A.M.; Gonz\u00e1lez-Rivero A.F.; Olmos J.M.; Hern\u00e1ndez J.L.; Llorca J.; Gonz\u00e1lez-Gay M.A.; Proprotein convertase subtilisin\/kexin type 9 in rheumatoid arthritis. Clin Exp Rheumatol 2016,34(6),1013-1019","journal-title":"Clin Exp Rheumatol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1055\/a-0833-4627","volume":"51","author":"Ferraz-Amaro I.","year":"2019","unstructured":"Ferraz-Amaro I.; Hern\u00e1ndez-Hern\u00e1ndez M.V.; Tejera-Segura B.; Delgado-Fr\u00edas E.; Mac\u00eda-D\u00edaz M.; Machado J.D.; Diaz-Gonz\u00e1lez F.; Effect of IL-6 receptor blockade on proprotein convertase subtilisin\/kexin type-9 and cholesterol efflux capacity in rheumatoid arthritis patients. Horm Metab Res 2019,51(3),200-209","journal-title":"Horm Metab Res"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13075-020-02386-7","volume":"23","author":"Frosteg\u00e5rd J.","year":"2021","unstructured":"Frosteg\u00e5rd J.; Ahmed S.; Hafstr\u00f6m I.; Ajeganova S.; Rahman M.; Low levels of PCSK9 are associated with remission in patients with rheumatoid arthritis treated with anti-TNF-\u03b1: potential underlying mechanisms. Arthritis Res Ther 2021,23(1),32","journal-title":"Arthritis Res Ther"},{"key":"ref=54","first-page":"18","volume":"38","author":"Ferraz-Amaro I.","year":"2020","unstructured":"Ferraz-Amaro I.; Delgado-Fr\u00edas E.; Hern\u00e1ndez-Hern\u00e1ndez V.; S\u00e1nchez-P\u00e9rez H.; de Armas-Rillo L.; Garc\u00eda-Dopico J.A.; D\u00edaz-Gonz\u00e1lez F.; Proprotein convertase subtilisin\/kexin type 9 in patients with systemic sclerosis. Clin Exp Rheumatol 2020,38(3)(Suppl. 125),18-24","journal-title":"Clin Exp Rheumatol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"452","DOI":"10.21037\/atm.2018.11.04","volume":"6","author":"Fang C.","year":"2018","unstructured":"Fang C.; Luo T.; Lin L.; Elevation of serum proprotein convertase subtilisin\/kexin type 9 (PCSK9) concentrations and its possible atherogenic role in patients with systemic lupus erythematosus. Ann Transl Med 2018,6(23),452","journal-title":"Ann Transl Med"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1177\/0961203320926253","volume":"29","author":"Liu A.","year":"2020","unstructured":"Liu A.; Rahman M.; Hafstr\u00f6m I.; Ajeganova S.; Frosteg\u00e5rd J.; Proprotein convertase subtilisin kexin 9 is associated with disease activity and is implicated in immune activation in systemic lupus erythematosus. Lupus 2020,29(8),825-835","journal-title":"Lupus"},{"key":"ref=57","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X20975904","volume":"12","author":"Sanchez-Perez H","year":"2020","unstructured":"Sanchez-Perez H; Quevedo-Abeledo JC; Tejera-Segura B; de Armas-Rillo L; Rua-Figueroa I; Gonzalez-Gay MA; Ferraz-Amaro I; Proprotein convertase subtilisin\/kexin type 9 is related to disease activity and damage in patients with systemic erythematosus lupus. Ther Adv Musculoskelet Dis 2020,12","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1002\/jcp.27254","volume":"234","author":"Tang Z.H.","year":"2019","unstructured":"Tang Z.H.; Li T.H.; Peng J.; Zheng J.; Li T.T.; Liu L.S.; Jiang Z.S.; Zheng X.L.; PCSK9: A novel inflammation modulator in atherosclerosis? J Cell Physiol 2019,234(3),2345-2355","journal-title":"J Cell Physiol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1161\/ATVBAHA.117.309630","volume":"37","author":"Sun L.","year":"2017","unstructured":"Sun L.; Yang X.; Li Q.; Zeng P.; Liu Y.; Liu L.; Chen Y.; Yu M.; Ma C.; Li X.; Li Y.; Zhang R.; Zhu Y.; Miao Q.R.; Han J.; Duan Y.; Activation of adiponectin receptor regulates proprotein convertase subtilisin\/kexin type 9 expression and inhibits lesions in apoe-deficient mice. Arterioscler Thromb Vasc Biol 2017,37(7),1290-1300","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"192","DOI":"10.4103\/ijd.IJD_114_18","volume":"64","author":"Seleit I.","year":"2019","unstructured":"Seleit I.; Bakry O.A.; Abd El Gayed E.; Ghanem M.; Peroxisome proliferator-activated receptor-\u03b3 gene polymorphism in psoriasis and its relation to obesity, metabolic syndrome, and narrowband ultraviolet B response: a case-control study in egyptian patients. Indian J Dermatol 2019,64(3),192-200","journal-title":"Indian J Dermatol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/dom.12819","volume":"19","author":"Laugier-Robiolle S.","year":"2017","unstructured":"Laugier-Robiolle S.; Verg\u00e8s B.; Le Bras M.; Gand E.; Bouillet B.; Saulnier P.J.; Le May C.; Pichelin M.; Mar\u00e9chaud R.; Petit J.M.; Hadjadj S.; Cariou B.; Glycaemic control influences the relationship between plasma PCSK9 and LDL cholesterol in type 1 diabetes. Diabetes Obes Metab 2017,19(3),448-451","journal-title":"Diabetes Obes Metab"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.2337\/dc16-2563","volume":"40","author":"Levenson A.E.","year":"2017","unstructured":"Levenson A.E.; Wadwa R.P.; Shah A.S.; Khoury P.R.; Kimball T.R.; Urbina E.M.; de Ferranti S.D.; Bishop F.K.; Maahs D.M.; Dolan L.M.; Biddinger S.B.; PCSK9 is increased in youth with type 1 diabetes. Diabetes Care 2017,40(7),e85-e87","journal-title":"Diabetes Care"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1001\/jama.2016.14568","volume":"316","author":"Lotta L.A.","year":"2016","unstructured":"Lotta L.A.; Sharp S.J.; Burgess S.; Perry J.R.B.; Stewart I.D.; Willems S.M.; Luan J.; Ardanaz E.; Arriola L.; Balkau B.; Boeing H.; Deloukas P.; Forouhi N.G.; Franks P.W.; Grioni S.; Kaaks R.; Key T.J.; Navarro C.; Nilsson P.M.; Overvad K.; Palli D.; Panico S.; Quir\u00f3s J.R.; Riboli E.; Rolandsson O.; Sacerdote C.; Salamanca E.C.; Slimani N.; Spijkerman A.M.; Tjonneland A.; Tumino R.; van der A, D.L.; van der Schouw, Y.T.; McCarthy, M.I.; Barroso, I.; O\u2019Rahilly, S.; Savage, D.B.; Sattar, N.; Langenberg, C.; Scott, R.A.; Wareham, N.J. Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: a meta-analysis. JAMA 2016,316(13),1383-1391","journal-title":"JAMA"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S2213-8587(16)30396-5","volume":"5","author":"Schmidt A.F.","year":"2017","unstructured":"Schmidt A.F.; Swerdlow D.I.; Holmes M.V.; Patel R.S.; Fairhurst-Hunter Z.; Lyall D.M.; Hartwig F.P.; Horta B.L.; Hypp\u00f6nen E.; Power C.; Moldovan M.; van Iperen E.; Hovingh G.K.; Demuth I.; Norman K.; Steinhagen-Thiessen E.; Demuth J.; Bertram L.; Liu T.; Coassin S.; Willeit J.; Kiechl S.; Willeit K.; Mason D.; Wright J.; Morris R.; Wanamethee G.; Whincup P.; Ben-Shlomo Y.; McLachlan S.; Price J.F.; Kivimaki M.; Welch C.; Sanchez-Galvez A.; Marques-Vidal P.; Nicolaides A.; Panayiotou A.G.; Onland-Moret N.C.; van der Schouw Y.T.; Matullo G.; Fiorito G.; Guarrera S.; Sacerdote C.; Wareham N.J.; Langenberg C.; Scott R.; Luan J.; Bobak M.; Malyutina S.; Paj\u0105k A.; Kubinova R.; Tamosiunas A.; Pikhart H.; Husemoen L.L.; Grarup N.; Pedersen O.; Hansen T.; Linneberg A.; Simonsen K.S.; Cooper J.; Humphries S.E.; Brilliant M.; Kitchner T.; Hakonarson H.; Carrell D.S.; McCarty C.A.; Kirchner H.L.; Larson E.B.; Crosslin D.R.; de Andrade M.; Roden D.M.; Denny J.C.; Carty C.; Hancock S.; Attia J.; Holliday E.; O\u2019Donnell M.; Yusuf S.; Chong M.; Pare G.; van der Harst P.; Said M.A.; Eppinga R.N.; Verweij N.; Snieder H.; Christen T.; Mook-Kanamori D.O.; Gustafsson S.; Lind L.; Ingelsson E.; Pazoki R.; Franco O.; Hofman A.; Uitterlinden A.; Dehghan A.; Teumer A.; Baumeister S.; D\u00f6rr M.; Lerch M.M.; V\u00f6lker U.; V\u00f6lzke H.; Ward J.; Pell J.P.; Smith D.J.; Meade T.; Maitland-van der Zee A.H.; Baranova E.V.; Young R.; Ford I.; Campbell A.; Padmanabhan S.; Bots M.L.; Grobbee D.E.; Froguel P.; Thuillier D.; Balkau B.; Bonnefond A.; Cariou B.; Smart M.; Bao Y.; Kumari M.; Mahajan A.; Ridker P.M.; Chasman D.I.; Reiner A.P.; Lange L.A.; Ritchie M.D.; Asselbergs F.W.; Casas J.P.; Keating B.J.; Preiss D.; Hingorani A.D.; Sattar N.; PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. Lancet Diabetes Endocrinol 2017,5(2),97-105","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.bbrc.2017.02.085","volume":"485","author":"Grune J.","year":"2017","unstructured":"Grune J.; Meyborg H.; Bezhaeva T.; Kappert K.; Hillmeister P.; Kintscher U.; Pieske B.; Stawowy P.; PCSK9 regulates the chemokine receptor CCR2 on monocytes. Biochem Biophys Res Commun 2017,485(2),312-318","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1093\/eurheartj\/ehx002","volume":"38","author":"Bernelot Moens S.J.","year":"2017","unstructured":"Bernelot Moens S.J.; Neele A.E.; Kroon J.; van der Valk F.M.; Van den Bossche J.; Hoeksema M.A.; Hoogeveen R.M.; Schnitzler J.G.; Baccara-Dinet M.T.; Manvelian G.; de Winther M.P.J.; Stroes E.S.G.; PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia. Eur Heart J 2017,38(20),1584-1593","journal-title":"Eur Heart J"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1161\/ATVBAHA.115.306032","volume":"35","author":"Demers A.","year":"2015","unstructured":"Demers A.; Samami S.; Lauzier B.; Des Rosiers C.; Ngo Sock E.T.; Ong H.; Mayer G.; PCSK9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver. Arterioscler Thromb Vasc Biol 2015,35(12),2517-2525","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1161\/CIRCULATIONAHA.120.046290","volume":"143","author":"Qi Z.","year":"2021","unstructured":"Qi Z.; Hu L.; Zhang J.; Yang W.; Liu X.; Jia D.; Yao Z.; Chang L.; Pan G.; Zhong H.; Luo X.; Yao K.; Sun A.; Qian J.; Ding Z.; Ge J.; PCSK9 (proprotein convertase subtilisin\/kexin 9) enhances platelet activation, thrombosis, and myocardial infarct expansion by binding to platelet CD36. Circulation 2021,143(1),45-61","journal-title":"Circulation"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1177\/1535370213503262","volume":"238","author":"Voloshyna I.","year":"2013","unstructured":"Voloshyna I.; Modayil S.; Littlefield M.J.; Belilos E.; Belostocki K.; Bonetti L.; Rosenblum G.; Carsons S.E.; Reiss A.B.; Plasma from rheumatoid arthritis patients promotes pro-atherogenic cholesterol transport gene expression in THP-1 human macrophages. Exp Biol Med (Maywood) 2013,238(10),1192-1197","journal-title":"Exp Biol Med (Maywood)"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2174\/1381612820666140825122525","volume":"21","author":"Krabben A.","year":"2015","unstructured":"Krabben A.; Huizinga T.W.; Mil A.H.; Biomarkers for radiographic progression in rheumatoid arthritis. Curr Pharm Des 2015,21(2),147-169","journal-title":"Curr Pharm Des"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1002\/art.22809","volume":"56","author":"Dixon W.G.","year":"2007","unstructured":"Dixon W.G.; Watson K.D.; Lunt M.; Hyrich K.L.; Silman A.J.; Symmons D.P.; Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007,56(9),2905-2912","journal-title":"Arthritis Rheum"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1136\/ard.2008.101964","volume":"68","author":"Choy E.","year":"2009","unstructured":"Choy E.; Sattar N.; Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 2009,68(4),460-469","journal-title":"Ann Rheum Dis"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s13167-017-0106-6","volume":"8","author":"Wici\u0144ski M.","year":"2017","unstructured":"Wici\u0144ski M.; \u017bak J.; Malinowski B.; Popek G.; Grze\u015bk G.; PCSK9 signaling pathways and their potential importance in clinical practice. EPMA J 2017,8(4),391-402","journal-title":"EPMA J"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","volume":"5","author":"Sabatine M.S.","year":"2017","unstructured":"Sabatine M.S.; Leiter L.A.; Wiviott S.D.; Giugliano R.P.; Deedwania P.; De Ferrari G.M.; Murphy S.A.; Kuder J.F.; Gouni-Berthold I.; Lewis B.S.; Handelsman Y.; Pineda A.L.; Honarpour N.; Keech A.C.; Sever P.S.; Pedersen T.R.; Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol 2017,5(12),941-950","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2337\/dc18-1491","volume":"42","author":"Leiter L.A.","year":"2019","unstructured":"Leiter L.A.; Teoh H.; Kallend D.; Wright R.S.; Landmesser U.; Wijngaard P.L.J.; Kastelein J.J.P.; Ray K.K.; Inclisiran lowers LDL-C and PCSK9 irrespective of diabetes status: the ORION-1 randomized clinical trial. Diabetes Care 2019,42(1),173-176","journal-title":"Diabetes Care"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12933-019-0951-9","volume":"18","author":"Ray K.K.","year":"2019","unstructured":"Ray K.K.; Del Prato S.; M\u00fcller-Wieland D.; Cariou B.; Colhoun H.M.; Tinahones F.J.; Domenger C.; Letierce A.; Mandel J.; Samuel R.; Bujas-Bobanovic M.; Leiter L.A.; Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies. Cardiovasc Diabetol 2019,18(1),149","journal-title":"Cardiovasc Diabetol"},{"key":"ref=77","unstructured":"Targeting Risk Factors for Diabetes in Subjects With Normal Blood Cholesterol Using Omega-3 Fatty Acids. Available from:  https:\/\/ClinicalTrials.gov\/show\/NCT04485871"},{"key":"ref=78","unstructured":"Effect of Alirocumab on Postprandial Hyperlipemia in Patients With Type 2 Diabetes. Available from:  https:\/\/ClinicalTrials.gov\/show\/NCT03344692"},{"key":"ref=79","unstructured":"The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascular Disease. Available from:  https:\/\/ClinicalTrials.gov\/show\/NCT03829046"},{"key":"ref=80","unstructured":"Expanded Combination of Evolocumab Plus Empagliflozin on Diabetes. Available from:  https:\/\/ClinicalTrials.gov\/show\/NCT03932721"},{"key":"ref=81","unstructured":"Cholesterol Lowering and Residual Risk in Type 2 Diabetes. Available from:  https:\/\/ClinicalTrials.gov\/show\/NCT043-69664"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1002\/jcp.26040","volume":"233","author":"Khademi F.","year":"2018","unstructured":"Khademi F.; Momtazi-Borojeni A.A.; Reiner \u017d.; Banach M.; Al-Rasadi K.A.; Sahebkar A.; PCSK9 and infection: A potentially useful or dangerous association? J Cell Physiol 2018,233(4),2920-2927","journal-title":"J Cell Physiol"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867328666210810150940","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/195505\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867328666210810150940","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T05:27:32Z","timestamp":1656566852000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/195505\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":82,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867328666210810150940","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-03-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}